38
Participants
Start Date
August 1, 2025
Primary Completion Date
July 31, 2026
Study Completion Date
December 31, 2026
Radiotherapy combined with immunotherapy
(1) SBRT 8Gy×3f, (2) LDRT 2Gy ×3f, PD-1/L1 inhibitor, periodically, until the disease progresses or intolerable toxic side effects, (4) GM-CSF, 200ug/QD, subcutaneous injection, the first course of treatment for 7 days.
RECRUITING
China-Japan Friendship Hospital, Beijing
China-Japan Friendship Hospital
OTHER